Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000019617-25-001004
Filing Date
2025-10-17
Accepted
2025-10-17 13:55:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5212
  Complete submission text file 0000019617-25-001004.txt   7251
Mailing Address 383 MADISON AVENUE NEW YORK NY 10017
Business Address 383 MADISON AVENUE NEW YORK NY 10017 2122706000
JPMORGAN CHASE & CO (Filed by) CIK: 0000019617 (see all company filings)

EIN.: 132624428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Subject) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87705 | Film No.: 251400033
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)